OWCP - OWC Pharmaceutical Research Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
0.247
-0.003 (-1.200%)
At close: 3:57PM EDT
Stock chart is not supported by your current browser
Previous Close0.250
Open0.250
Bid0.000 x 0
Ask0.000 x 0
Day's Range0.240 - 0.255
52 Week Range0.200 - 1.140
Volume235,213
Avg. Volume1,081,561
Market Cap36.14M
Beta-10.10
PE Ratio (TTM)N/A
EPS (TTM)-0.033
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders
    PR Newswirelast month

    OWC Pharmaceutical Research Corp. Issues Chairman's Statement to Shareholders

    PETACH TIKVA, Israel, March 8, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a chairman's statement to shareholders. In the light of recent events, and the numerous communications we have received from shareholders, I would like to address this statement to the Shareholders of OWCP (the "Company"). The Company is committed to building a leadership position in the medical cannabis market and to our mission of improving patients' lives through the development of new solutions, products and devices derived from and delivery mechanisms for the use of medical cannabis.

  • OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer
    PR Newswire2 months ago

    OWC Pharmaceutical Research Corp. Appoints Dr. Oron Yacoby Zeevi as its Chief Scientific Officer

    RAMAT GAN, Israel, Feb. 20, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Oron Yacoby Zeevi as its Chief Scientific Officer (CSO). Dr. Yacoby Zeevi has more than 20 years of extensive scientific experience with both private and publicly listed companies in the biopharmaceutical industry.

  • The Wall Street Journal2 months ago

    Corrections & Amplifications

    Corrections & Amplifications for the edition of Feb. 5, 2018.

  • PR Newswire3 months ago

    OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference

    OWC Pharmaceutical Research Corp. [OWC Pharma](OWCP) is pleased to announce it will be a Diamond Sponsor at the 2018 Wall Street Conference. This is second consecutive year OWC Pharma will be attending this prestigious investment conference to be held on February 21st , 2018 at the Hilton Doubletree Hotel & Convention Center in Boca Raton, Florida. The Wall Street Conference is one of the premiere conferences in the venture capital arena and Small Cap marketplace.

  • OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet
    PR Newswire4 months ago

    OWC Pharmaceutical Research Corp. Announces Update on its Proprietary Medical Cannabis Sublingual Tablet

    PETACH TIKVA, Israel, Dec. 21, 2017 /PRNewswire/ -- In December 2017, OWC Pharmaceutical Research Corp (OWCP) received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet (the "Tablet") for the administration of medical cannabis.

  • PR Newswire7 months ago

    OWC Pharma Issues Chairman's Letter to Shareholders

    OWC Pharma (OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today issued a letter to shareholders. Following my recent appointment as Chairman at OWC Pharma (OWCP), it is my pleasure to introduce myself to you and to initiate a new tradition of biannual shareholder update letters.

  • PR Newswire9 months ago

    OWC Pharmaceutical Research Corp Appoints Dr. Stanley Hirsch as its Active Chairman

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced the appointment of Dr. Stanley Hirsch as its active chairman of the board of directors. Dr. Stanley Hirsch, age 59, has had extensive scientific, executive and board level experience for more than the past 25 years in private and publicly listed companies in biopharmaceutical and agricultural biotech industries, among others, including direct experience in raising capital and leading M&A activity together with multi-cultural management skills, having managed companies in Israel, Brazil, UK, China and the United States.

  • Marketwired9 months ago

    CFN Media Exclusive Interview with OWCP's Dr. Sharon Rozenblat

    CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article and exclusive interview with Dr. Sharon Rozenblat, Advisory Board ...

  • PR Newswire9 months ago

    OWC Pharmaceutical Research Takes Further Actions to Protect its Intellectual Property

    OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the European Union Patent and Trademark Office for its active cannabinoid-based psoriasis topical cream.

  • PR Newswire10 months ago

    OWC Pharmaceutical Research Corp. Announces Market Readiness of its Cannabinoid-based Topical Cream for Skin Conditions Starting With Psoriasis

    OWC Pharmaceutical Research Corp. (OWCP) today announced that its wholly-owned, Israel-based subsidiary, One World Cannabis Ltd. (OWC), has filed a patent application with the United States Patent and Trademark Office for its active cannabinoid-based topical cream. This new patent application follows the previously filed 'provisional' patent application.

  • Marketwired10 months ago

    OWC Pharmaceuticals Engages CFN Media to Cultivate New Investor Audience & Communicate with Existing Shareholders

    CFN Media Group , the leading agency and digital media network dedicated to the North American cannabis industry, today announced that OWC Pharmaceutical Research Corp. has engaged CFN Media to conduct ...

  • PR Newswire11 months ago

    OWC Pharmaceutical Research Corp. Enters Into a Strategic Relationship With Germany-Based mediq Innovation Experts

    OWC Pharmaceutical Research Corp. (OWCP) and mediq Innovation Partners (mediq) are pleased to announce an agreement for the introduction of OWCP's active cannabinoid-based topical psoriasis cream to the German market. Frankfurt, Germany-based mediq has extensive experience, knowledge and a successful track record in enabling Israel-based companies to penetrate the European markets.

  • PR Newswirelast year

    OWC Pharmaceutical Research Announces Update on Multiple Myeloma Study

    OWC Pharmaceutical Research Corp. (OWCP), ("OWC" or the "Company"), an Israeli-based research company engaged in the development of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, today announced that the Scientific Advisory Team of its wholly owned Israeli subsidiary, One World Cannabis Ltd. ("OWC") has determined the road map for continuing the Multiple Myeloma study.